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Abstract
Background: CHK2 kinase is a tumor suppressor that plays important role in DNA damage
signaling, cell cycle regulation and DNA damage induced apoptosis. CHK2 kinase expression was
known to be ubiquitous in mammalian cells. CHK2-/- cells were remarkably resistant to DNA
damage induced apoptosis, mimicking the clinical behavior of non-small cell lung cancer to
conventional chemo and radiation therapy.
Result: We reported that the CHK2 expression is diminished or absent in both non-small cell lung
cancer (NSCLC) cell lines and clinical lung cancer tumor specimens. The absent CHK2 expression
in NSCLC was due to hypermethylation of the CHK2 gene promoter, preventing from binding of
a transcriptional factor, leading to silence of the CHK2 gene transcription.
Conclusion: Since the CHK2 null mice showed a remarkable radioresistance, which bear
significant similarity to clinical behavior of NSCLC, down-regulation of CHK2 kinase expression by
CHK2 gene silencing and methylation in non-small cell lung cancer suggest a critical role of CHK2
kinase in DNA damage induced apoptosis and a novel mechanism of the resistance of NSCLC to
DNA damage based therapy.
Introduction
CHK2 kinase is an important cell cycle regulator in DNA
damage response pathway. In response to exogenous or
endogenous DNA damage agents, CHK2 is phosphor-
ylated and activated by ATM kinase at the Thr68, and the
activated CHK2 phosphorylates a number of downstream
targets including CDC25, BRCA1, p53, E2F and others
that are important in cell cycle checkpoint control, DNA
damage repair and DNA-damage-induced apoptosis [1-5].
CHK2 germline mutation was found to associate with a
subset of Li-Fraumeni syndrome (LFS), a cancer predis-
posing familiar syndrome with a majority of patients car-
rying p53 mutations [6], although this notion was
challenged by some recent studies [7,8]. Somatic muta-
tions of CHK2 gene have been found in subsets of diverse
types of human cancers including breast, lung, vulva,
colon, ovary, osteosarcoma, and lymphomas (see review
in [9]). The majority of these mutations were missense
mutation, base deletion or conversion resulting truncated
Published: 04 May 2004
Molecular Cancer 2004, 3:14
Received: 16 March 2004
Accepted: 04 May 2004
This article is available from: http://www.molecular-cancer.com/content/3/1/14
© 2004 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.
Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/14
Page 2 of 10
(page number not for citation purposes)
proteins, some of which have been characterized at the
protein levels [10].
Normal CHK2 gene is located at chromosome 22 [7].
There are multiple copies of CHK2 homologous
sequences within the genome, particularly at the 3' end of
the coding sequence. Totally six homologous sequence
fragments at the chromosome 5, 7, 10, 15, 16, 22 and X
were found encompassing the exon 10 to 14 of the CHK2
genes and share 95–98% sequence similarity. These
homologous sequences within the genomic DNA compli-
cate the mutation analysis of the CHK2 gene [6,7]. It is
also reported that some of these CHK2 homologous
sequences are not transcribed, and therefore nonfunc-
tional [6]. The effect of multiple copies of CHK2 homolo-
gous sequences on normal CHK2 gene transcription and
possibly translation is yet to be elucidated.
Lung cancer remains to be the leading killer in cancer
death. Lung cancer is generally classified as small cell lung
cancer (20% of total patients) and non-small cell lung
cancer (80%). The major problem for lung cancer treat-
ment is the natural resistance of cancer cells to conven-
tional therapy. The burning question in lung cancer
treatment is how to overcome the resistance of cancer cells
to DNA damage agents such as cisplatin or ionizing radi-
ation (IR) [11]. Increasing evidence suggests that CHK2
kinase plays a critical role in DNA damage induced apop-
tosis. CHK2 knockout mice showed that the CHK2 null
cells were remarkably resistant to IR induced apoptosis
[4,12]. The radioresistant phenotypes of the CHK2 knock-
out mice bear significant similarity to the clinical behavior
of human non-small cell lung cancer to chemoradiation
therapy. We report here that the CHK2 protein expression
is down-regulated through hypermethylation of the
CHK2 gene promoter in both the non-small cell lung can-
cer cell lines and the human non-small cell lung cancer
tumor tissues. The lung cancer cell lines were known to be
resistant to cisplatin, a leading chemotherapy drug. These
results suggest an important role of CHK2 kinase in cispl-
atin-induced apoptosis of the tumor cells, and potentially
a novel molecular mechanism for the natural resistance of
human non-small cell cancer to DNA-damage induced
therapy.
Results
CHK2 expression is markedly diminished in non-small cell 
lung cancer cell lines
We have determined the expression level of CHK2 kinase
in the lung cancer cell line A549 in response to cisplatin
(Fig 1). We used the ovarian cancer cell A2780 as a con-
trol. The level of CHK2 kinase expression was detectable
by immunoblot analyses in the control A2780 ovarian
cancer cells, and not detected in A549 cells. Additionally,
CHK2 expression was detected in H69 cells, a small cell
lung cancer cell line, but not in another non-small cell
lung cancer cell line H460 cells. The level of CHK2 expres-
sion in H69 cells was decreased in response to cisplatin.
These results indicate that the CHK2 expression levels vary
in different cancer cell lines, and appear to be markedly
diminished in the non-small cell lung cancer cells A549
and H460 cells. Since CHK2 kinase appears to be critical
in regulation of DNA-damage induced apoptosis in the
knockout mice models, we attempted to correlate the
tumor cell sensitivity to cisplatin in four different cancer
cell lines. IC50 of cisplatin for these four different cancer
cell lines have been previously documented (Table 1). It
at least appears that CHK2 expression levels correlate with
cisplatin sensitivity, although more definitive studies are
required to reach the conclusion.
Expression of the CHK2 mRNA is significantly decreased in 
non-small cell lung cancer cell lines
Based upon the above results, we sought to determine the
level of CHK2 mRNA in the cancer cell lines. It is reported
that there are multiple CHK2 homologous DNA
sequences within the genome located at the various chro-
mosomes [6,7]. There was only one species of CHK2
mRNA detected within both the ovarian cancer and lung
cancer cell lines by Northern blot analyses using full-
length CHK2 cDNA as a probe (Fig 2A). In contrast to
A2780 and H69 cells where abundant CHK2 mRNA was
CHK2 expression is markedly diminished or absent in non-small c ll lung ca cer cell lines by immunoblotting analysisFigure 1
CHK2 expression is markedly diminished or absent in non-
small cell lung cancer cell lines by immunoblotting analysis: 
The cells were treated with cisplatin (33 µM) for the time 
listed above, and the total cell lysates were harvested and 
analyzed by immunoblotting with anti-CHK2 polyclonal anti-
body. β-actin was used to normalize the loading in the each 
lane.
Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/14
Page 3 of 10
(page number not for citation purposes)
present, there was significantly decreased expression of
CHK2 mRNA in H460 cells, and non-detectable in A549
cells.
To further confirm the absence or the decrease of the
CHK2 kinase mRNA in the non-small cell lung cancer cell
lines, we obtained a panel of non-small cell lung cancer
cell lines from ATCC (H5875, H522, A549, HTB53,
H1395, H441, H2342, H2170, H2228, H2286, H520 and
NHBE). NHBE is a normal human bronchial epithelial
cell line. We used semi-quantitative PCR analyses to deter-
mine the level of the CHK2 kinase mRNA in these cell
lines (Fig 2B). The PCR primers for CHK2 were as
described in the material and method section. The
GAPDH primers were as described previously [13]. Totally
5 of the 11 cell lines showed expression of CHK2 mRNA,
and 6 cell lines were negative by PCR analyses (Fig 2B).
Normal bronchial epithelia cells readily expressed normal
CHK2 mRNA. These results suggest that the diminished
expression of CHK2 protein in non-small cell lung cancer
cell lines is at least in part due to decreased expression of
CHK2 mRNA in these cells. Furthermore, abnormal
CHK2 mRNA expression in non-small cell lung cancer cell
lines is a frequent, rather than rare observation.
The promoter of the CHK2 gene is methylated in non-
small cell lung cancers
Since A549 and H460 cells are both non-small cell lung
cancer cells, and hypermethylation of genes is well-docu-
mented in lung cancer, we determined to see if the
decreased CHK2 mRNA expression is due to methylation
of the CHK2 gene promoter. Using a web-based software
CpG island searcher, we analyzed the CHK2 gene
promoter sequence (Genbank accession number AL
117330) to see if there is a CpG rich regions. Between -615
and -411 of the CHK2 gene promoter (refers to the start of
translation as +1), there is a region of DNA sequence that
is rich in CpG islands, the potential hypermethylation
sites (Fig 3A). We used methylation specific PCR tech-
niques (MSP) to determine the methylation status of the
CHK2 promoter in both the lung cancer cell lines and the
patient's tumor samples using the oligonucleotide prim-
ers as shown in Table 2. The PCR products were cloned
into TOPO T-A cloning vector and sequenced by commer-
cial sequencing services (Certigen Inc., Lubbock, TX).
There was methylation of CHK2 promoter present in the
A549 and H460 cells, but no methylation detected within
A2780 cells (Fig 3B).
We tested to see if demethylating agents, such as 5-aza-
cytidine, can re-activate the CHK2 gene expression in both
A549 and H460 cells by using immunoblot analyses. We
treated the A549 and H460 cells for up to 5 days with 5
µM 5-aza-cytidine, and no reactivation of the CHK2 gene
expression was detected (data not shown).
Table 1: IC50 concentration of Cisplatin
Cell type A2780 H69 A549 H460
Cisplatin 3 µM 0.17 µM 64 µM 80 µM
CHK2 +++ +++ --- ±
A: Expression of the CHK2 mRNA is significantly decreased in A549 and H460 cells, but not in H69 and A2780 cellsFigure 2
A: Expression of the CHK2 mRNA is significantly decreased 
in A549 and H460 cells, but not in H69 and A2780 cells: 
Totally 20 µg RNA was used in each lane. The 18S and 28S 
rRNAs were used to normalize the loading of RNA sample in 
each lane. The probe was full-length CHK2 cDNA. B: Semi-
quantitative RT-PCR analyses of the CHK2 mRNA expres-
sion in 11 non-small cell lung cancer cell lines. NHBE is a nor-
mal bronchial epithelial cell line. GAPDH was used to 
normalize the experimental conditions.
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The promoter of the CHK2 gene is methylated in non-small cell lung cancersFigure 3
The promoter of the CHK2 gene is methylated in non-small cell lung cancers: A: The CHK2 gene promoter sequence from -
615/-411 from the Genbank (AL117330). The putative transcriptional factor binding sites were underlined and potential CpG 
islands were bold and highlighted. B: Methylation specific PCR analyses of the genomic DNA isolated from the cancer cell lines: 
W- the wild type primers, M- methylation specific primers, U-unmethylation specific primers. The expected PCR product was 
205 bps, and confimed by DNA sequencing analyses. C: Methylation specific PCR analyses of the genomic DNA isolated from 
the primary non-small cell lung cancer tumor specimens. Pt 7 was the normal match lung control from the patient 6 (tumor).
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We further tested 10 primary lung cancer tumor samples
and one matched normal lung control tissues. The lung
tumor tissues were obtained from The Tumor Tissue Bank
at the West Virginia University with appropriate internal
review board approval (IRB). The genomic DNA was
extracted from the fresh frozen tumor samples using Qia-
gen Tissue extraction kit. The genomic DNA was subjected
to MSP analyses (Fig 3C). Patient 7 was the matched nor-
mal control lung tissue from the patient 6. Methylation of
the CHK2 gene promoter was detected in all the lung
tumor samples, but not in the normal control lung tissue
(pt 7). These results demonstrated that the CHK2 gene
promoter is preferentially methylated within both the
lung cancer cell lines and the lung cancer tumor tissues,
but not in the ovarian cancer cells or the matched normal
control lung tissue.
CHK2 kinase expression is decreased in lung cancer tumor 
specimens by immunohistochemistry
We used the primary lung cancer tumor tissue microarray
in combination with conventional immunohistochemi-
cal staining and automated imaging analyses to evaluate
the expression level of CHK2 kinase in human primary
lung cancer tumor samples. High-density human lung
cancer tumor tissue array slides were obtained from Cli-
nomics Biosciences Inc. (Pittsfield, MA) and stained with
the anti-CHK2 antibody as described. The staining results
were digitally acquired and analyzed using ACIS system
(Chroma Vision, San Juan Capistrano, CA). Table 3 sum-
marized the results of 46 non-small cell lung cancer tumor
samples and 41 normal matched lung control tissues. In
contrast to the matched normal lung control tissues in
which moderate or strong stains for CHK2 kinase were
observed (total score of 6 or 9), 83% non-small cell lung
cancer tumors stained weakly to non-detectable (total
score less than 3) (Fig 4A). The immunostaining signals
were only observed within the nuclei, not in cytoplasm.
Representative staining of both negative and positive sig-
nals were shown in Fig 4B. We performed the same immu-
nohistochemical staining for addition 46 non-small cell
lung cancer tumor specimens individually, and we have
found essentially identical results as described for the
tumor tissue microarray study (Data not shown). These
results demonstrated that the CHK2 expression levels in
non-small cell human lung cancer tumors are significantly
decreased by immunohistochemical staining method in
totally 92 lung cancer tumors.
Methylation of the CHK2 promoter silenced the 
transcription and prevented from binding of the 
transcriptional factor(s)
We cloned the DNA sequence between -615/-411 of the
wild type CHK2 proximal promoter amplified by the wild
type PCR primers as described above into a luciferase
reporter gene vector pGL3-promoter, and used the chi-
meric construct in transient transfection assays to deter-
mine if the proximal promoter -615/-411 of the CHK2
gene is functionally important for the CHK2 gene tran-
scription (Fig 5A). The positive control plasmid reporter
was from Promega Corp. and the promoter and enhancer
were derived from SV40 virus (Promega Corp. Madison,
WI). The CHK2 promoter sequence was tested to be active
Table 2: Oligonucleotide primers used for MSP
Wild Type forward (-615) CCTCC CGGGCTCAAG CGATTCTCCT GCCT (-587)
Methylated forward (-615) TTTTT CGGGTTTAAG CGATTTTTTT GTTT (-587)
Unmethylated forward: (-615) TTTTT TGGGTTTAAG TGATTTTTTT GTTT (-587)
Wild type reverse: (-411) GCGCGGGGGT TCACTCCTGT AGTCCCGCA (-439)
Methylated reverse: (-411) ACGCGAAAAT TCACTCCTAT AATCCCGCA (-439)
Unmethylated reverse: (-411) ACACAAAAAT TCACTCCTAT AATCCCACA (-439)
Table 3: Expression of CHK2 in Lung Tumors
Tumor Type Nuclear % Positive Nuclear Intensity Total score
Non-small cell carcinoma (n = 46) 3 1 3 (n = 38) (83%)
3 2 6 (n = 7) (15%)
3 3 9 (n = 1) (2%)
Normal Lung (n = 41) 3 1 3 (n = 4) (10%)
3 2 6 (n = 19) (46%)
3 3 9 (n = 18) (44%)
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in all cell lines (data not shown). Furthermore, in vitro
methylation of the chimeric construct using SSS I CpG
methylase and S-adenosylmethionine significantly
abolished the transcriptional activity of the CHK2 pro-
moter nearly 90–95%. These results indicate that the
CHK2 gene promoter is highly sensitive to methylation,
and the -615/-411 region of the CHK2 promoter is criti-
cally important for CHK2 gene activation.
We used the same fragment of the promoter DNA labeled
radioactively as a probe for gel mobility shift assays to
determine if there is one or more transcriptional factor(s)
binding to the DNA sequence, and if methylation of the
DNA sequence will influence the binding of the transcrip-
tional factor (s) (Fig 5B). As expected, there was one
prominent protein-DNA complex with the nuclear extract
from the A549 cells that can be effectively competed with
the unlabeled probe DNA (50X). We methylated the
probe DNA in vitro using SSS I CpG methylase and S-ade-
nosylmethionine, and used the in vitro methylated probe
DNA as the unlabeled competitor (50X) for the DNA-pro-
tein binding assays. In vitro methylation of the probe
DNA abolished the binding activity of the probe as dem-
onstrated by failure to compete with the wild type DNA
probe for binding to the transcriptional factor.
Discussion and conclusion
CHK2 kinase is an important component of the DNA
damage-signaling pathway. The critical role of CHK2
kinase in mediating the DNA damage signal was demon-
strated by using the knockout mice model in which G1/S
checkpoint defect and a remarkable radioresistance were
observed [12,14]. Furthermore, the function of CHK2
kinase appears to relate to p53 stabilization/accumulation
and the regulation of the p53 regulated target genes, such
as Bax, Noxa and Puma that are important for DNA dam-
age-induced apoptosis [12,15,16].
We have demonstrated that the CHK2 kinase expression is
regulated at the transcriptional level in non-small cell
lung cancer cell lines and the patients' tumor samples. The
protein expression level of the CHK2 kinase in lung cancer
was significantly diminished to non-detectable levels.
This decreased expression of CHK2 kinase is due to the
hypermethylation of the CHK2 promoter sequence. In
lung cancer, hypermethylation of the promoter sequences
leading to gene silence is common, and many genes
critical for cell cycle regulation and cell proliferation, such
as p16, p21, p14, and RARβ, were reported to be silenced
by promoter methylation [17-19].
It is a well-known clinical fact that the non-small cell lung
cancer is resistant to conventional chemoradiation ther-
apy, and the current therapeutic regimens are far from
optimal [11,20]. The molecular mechanism of the resist-
ance of the lung cancer cells to cisplatin and radiation is
unclear. The conventional cisplatin based chemotherapy
and radiation therapy are, in principle, DNA damage
based therapies, and result in DNA-damage induced
tumor cell apoptosis. Many genes, such as p53, BCL-2
gene family proteins are implied in the apoptotic proc-
esses [21]. Recently, the p53-regulated BH3-only proteins
such as Noxa and Puma were found to be critical in induc-
tion of apoptosis by chemotherapeutic agents [15,16].
Genetically, CHK2 kinase functions as an activator of the
p53 tumor suppressor [4,12,14]. It is attempting to spec-
ulate that the lack of the CHK2 kinase expression in the
non-small cell lung cancer mimics the CHK2 knockout
mice in which a radioresistance of the CHK2-/- cells were
noted, since the clinical behavior of the non-small cell
lung cancer is remarkably similar to the feature of the
CHK2-/- cells. Preliminary attempt to restore the CHK2
function in the non-small cell lung cancer cell lines A549
and H460 failed, since the CHK2 kinase alone appears to
CHK2 kinase expression is decreased in lung cancer tumor specimens by immunohistochemistryFigure 4
CHK2 kinase expression is decreased in lung cancer tumor 
specimens by immunohistochemistry. A: Graphic representa-
tion of the data summarized in Table 3. B: Representative 
immunostaining of the lung cancer tissue microarray with 
anti-CHK2 antibody.
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Methylation of the CHK2 gene promoter inhibited the CHK2 gene transcription and prevented from binding of the transcrip-tional f ctorFigure 5
Methylation of the CHK2 gene promoter inhibited the CHK2 gene transcription and prevented from binding of the transcrip-
tional factor: A: CHK2 promoter sequence -615/-411 was cloned into pGL3 luciferase reporter gene, and transfected into 
A549 cells, and the luciferase activity was assessed to determine the function of the CHK2 promoter sequence. WT-CHK2 
represented a wild type sequence of the CHK2 promoter. M-WT-CHK2 represented in vitro methylated wild type CHK2 pro-
moter by SSS I CpG DNA methylase. B: gel mobility shift assays using the wild type -615/-411 sequence of the CHK2 promoter 
as a probe. The unlabeled probe was 50X in excess, and the M-cold probe (50X in excess) was in vitro methylated wild type -
615/-411 DNA as unlabeled competitor for binding.
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induce apoptosis in these cells without addition of cispla-
tin (Zhang, P. unpublished). Such examples have been
described for p53 tumor suppressor in leukemic cells [22].
The ATM-CHK2-p53-BCL-2 family members pathway
seems to be one of the important mechanisms leading to
resistance of lung cancer.
We have demonstrated the down-regulation of the CHK2
kinase expression by methylation of the CHK2 gene pro-
moter in non-small cell lung cancer. We have identified a
region of -615/-411 of the CHK2 gene promoter that is
important for transcriptional activation. The transcrip-
tional factor binding to this region of DNA sequence is
unclear at this time. It has been reported that Sp1 gene
family members bind to the similar CG-rich sequences,
and the binding can be prevented by methylation [23-25].
It is likely that the transcriptional factor binding to the -
615/-411 sequence of the CHK2 gene promoter is of Sp1
gene family members, such as Sp1 and Sp3. We are
actively pursuing this direction with a hope to identify a
positive regulator of the CHK2 gene transcription so that
we could potentially increase the CHK2 expression in the
lung cancer cells.
We have also noted that the CHK2 kinase is degraded in
response to cisplatin treatment in the ovarian cancer
A2780 cells and the small cell lung cancer H69 cells (Fig
1, Zhang, P., unpublished result). The degradation of
CHK2 kinase in response to cisplatin treatment in these
cells appears at the protein level (unpublished). These
results suggest that the CHK2 kinase expression is regu-
lated at both the transcriptional level and post-transla-
tional (the protein) level. The detailed mechanism of the
CHK2 degradation is under investigation.
Finally, although the expression of CHK2 kinase was
reportedly ubiquitous in the normal cells and tissues [9],
the expression of CHK2 kinase in cancer cells are not.
Many of the cancer cells from the patients, such as colon
cancer, testicular embryonal carcinoma, do not express
CHK2 kinase, whereas the testicular seminoma express
high level of CHK2 kinase (data not shown). Whether the
absence of CHK2 kinase expression in these tumors corre-
lates closely with resistance of these tumors to DNA dam-
age inducing therapy, such as chemo and radiation
therapies, requires further study.
Recent work by Matsui, et al identified the transcription
start site of the CHK2 gene [26]. Based upon the start site
of transcription in their work, the region in this manu-
script identified to be hypermethylated is in fact in the
intron 1, rather than a promoter region.
Materials and methods
Immunoblot analyses
The immunoblot analysis of various proteins were per-
formed as described previously [27]. Briefly, the total cel-
lular proteins were separated on 10% polyacrylamide gels
under SDS denaturing conditions and electrophoretically
transferred to nitrocellulose membrane (Biorad Inc, CA).
The membranes were blocked with 5% non-fat milk solu-
tion and incubated for 1 h with a 1:200 dilution of pri-
mary antibodies (all from Santa Cruz Biotechnologies,
CA). After washing off the unbound antibodies several
times with 1 × TBS-Tween 20, the membranes were incu-
bated for 1 hour with a 1:2,000 dilution of sheep anti-rab-
bit horseradish peroxidase-conjugated IgG (Santa Cruz
Biotechnologies, CA) and washed several times. Immun-
odetection was performed with a chemiluminescence
Western blotting kit according to the supplier (Pierce Bio-
technology, Inc. Rockford, IL).
Northern blot analyses
Total RNA was isolated from the cultured cells or the
tumor tissues from the patients using TriZol reagent (Inv-
itrogen, San Diego CA). Totally 20 µg of RNA was used for
each lane for Northern blot analyses. The RNA was loaded
on to 1.2% formaldehyde agarose gel. The RNA was blot-
ted onto nylon membrane (Hybond N, Amersham Bio-
sciences, Inc.), and the membrane was UV crosslinked
according to standard procedures. Full length CHK2
cDNA was amplified by PCR based on the sequence from
the expression vector kindly provided by Dr. Junjie Chen
at Mayo Clinic. The cDNA probe was labeled by random
priming using a Prime-A-Gene labeling kit (Promega
Corp., Madison, WI) as instructed by the manufacturer.
Hybridization overnight at 65°C was followed by washes
(2 × 15 min at room temperature in 2 × SSC, 1% SDS and
then 2 × 30 min at 68°C in 0.1 × SSC, 1% SDS). The
results were analyzed by using Phosphoimager (Molecu-
lar Dynamics Inc.).
Semiquantitative PCR analyses of CHK2 expression in cell 
lines
A panel of non-small cell lung cancer cell lines were
obtained from ATCC, and cultured under the conditions
following the ATCC instruction. The total RNA was iso-
lated from these cells using TriZol reagent (Invitrogen,
San Diego CA) as previously described [13]. Reverse tran-
scription and PCR analyses were performed using the First
Stranded cDNA synthesis kit from Invitrogen, CA. The
PCR primers for CHK2 kinase were the following: For-
ward primer: 5'-ATGTCTCGGGAGTCGGATGT-3',
Reverse: 5'-TCACAACACAGCAGCACACA-3'. The PCR
product is the full-length coding region of the human
CHK2 kinase based upon the cDNA sequence under the
Genbank accession #AF174135. The relative expression
Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/14
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level of the CHK2 mRNA was normalized with the
GAPDH levels within the same cells.
Methylation specific PCR (MSP) analyses of the CHK2 
promoter
Methylation-specific PCR analyses of the genomic DNA
isolated from the cell lines and the tumor specimens were
essentially identical as described [28,29]. Methylation and
unmethylation specific primers were selected based upon
the sequences identified by the computer software CpG
Island Searcher http://www.uscnorris.com/cpgislands/
cpg.cgi. The primers are centered within the proximal pro-
moter region at -615 to -411 of the CHK2 promoter. These
primers listed in Table 2 were used for MSP studies of the
genomic DNA isolated from the non-small cell lung can-
cer A549 and H460 cells, ovarian cancer A2780 cells and
11 tumor specimens from primary non-small cell lung
cancer patients. The genomic DNA was isolated using Qia-
gen Tissue DNA extraction kit following the manufac-
turer's instruction. Totally 1 µg DNA was denatured by
NaOH and treated with 3 M sodium bisulfite, 10 mM hyd-
roquinone for 16 hours at 50°C as described [28]. The
modified DNA was purified using Wizard DNA purifica-
tion system as described [28,29] and used for MSP assays.
The expected PCR product of 205 bp- fragment was visu-
alized by 2.0% agarose gel and ethidium bromide stain-
ing. The PCR products from each pair of primers was
cloned into TA-cloning vector and sequenced to confirm
the methylation status of each amplified fragments as
described [28,29].
Luciferase reporter assays
We cloned the wild type promoter fragment amplified
from MSP into luciferase reporter vector to test the func-
tion of the promoter fragment in A2780, A549 and H460
cells to ensure the promoter that is methylated is func-
tionally important in these cells. One microgram of the
chimeric reporter construct was transfected into the lung
cancer cell lines A549 and H460 cells and the ovarian can-
cer A2780 cells in the 6-well plates for 24 hours using
Lipofectamine 2000 (Invitrogen, CA). After 24 hours, the
total cell lysates were harvested for luciferase assays using
Luciferase assay system (Promega Corp. WI). The total
proteins from the cell lysates were quantified using Brad-
ford protein assay system (Biorad Inc. CA) and used to
normalize the luciferase activity.
To assess the effect of methylation of the CHK2 gene pro-
moter sequences on its function, we used SSS I CpG meth-
ylase (New England Biolabs, MA) to methylate the wild
type CHK2-luciferase reporter construct in vitro and use
the methylated reporter plasmid for transfection and luci-
ferase assays. In vitro methylation was performed as
instructed by the manufacturer. Briefly, 5 microgram of
the reporter plasmid was incubated with 10 units of SSS I
CpG DNA methylase overnight in the presence of 160 µM
S-adenosylmethionine. The methylated plasmid was
purified using Qiagen micro-column before being used
for transfection.
Gel mobility shift assays
We also used the WT PCR product of the CHK2 promoter
between -615/-411 amplified in the MSP assays as a probe
for mobility gel shift assays to see if the promoter
sequence is bound to a transcriptional factor. The 205-bp-
fragment was amplified by PCR using genomic DNA and
labeled with T4 polynucleotide kinase and γ-32P-ATP.
The labeled probe was purified using Micro-spin column
to remove the un-incorporated radioactive material. The
gel mobility shift assays were performed as previously
described [30]. The nuclear extracts were prepared from
A549, H460 and A2780 cells as described [30]. Unlabeled
probe (50X in excess) was used for competition.
We also used SSS I CpG methylase (New England Biolabs,
MA) to methylate the wild type -615/-411 fragment in
vitro as described above and used the methylated probe
(50X in excess) to compete with the wild type probe for
nuclear protein binding.
Immunohistochemical staining and the automated 
imaging analyses
We used immunohistochemical staining in combination
with automated imaging analyses to detect the presence of
CHK2 protein in the primary lung cancer tumor speci-
mens. We have obtained the high-density lung cancer
tumor tissue array slides from Clinomics Biosciences Inc.
(Pittsfield, MA). We used classic immunohistochemical
staining method to detect the CHK2 protein expression
using anti-CHK2 antibody (Santa Cruz Biotechnologies
Inc. CA). The high-density lung cancer tissue micro-array
slides consist of 46 non-small cell lung cancer tumors, 4
small cell lung cancer tumors, more than 200 normal tis-
sues including lung, liver, brain etc. The slides were sec-
tioned at 5 micron in thickness, de-paraffinized in xylene,
dehydrated, rehydrated in a series of 100%, 90% and 70%
ethanol, and stained with the CHK2 antibody in the Ven-
tana Benchmark II Autostainer (Ventana Medical Interna-
tional Inc. AZ).
After staining, the slides were digitized, acquired, and the
densitometric quantitation was analyzed by using Auto-
mated Cellular Imaging System (ACIS, Chroma Vision,
San Juan Capistrano, CA). The scoring system we have
used for the result analysis was essentially as described by
others [31,32]. Briefly, the total area of the micro-core was
scanned and acquired by the ACIS software of the imag-
ing/microscopy system, and the stained tumor cells for
CHK2 expression were quantified as follows. Scores of 1–
3 were assigned according to the percentage of positive
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tumor cells (1, <25%; 2, 25–50%; 3, >50%) and the stain-
ing intensity of the tumor cells (score 1 for 0–25%, score
2 for 25–50%, score 3 for >50%). The two scores were
multiplied to give an overall score of 1–9, where 1–3 is
considered weak, 4–6 is moderate, and 9 is strong staining
[32]. The imaging analysis has been previously described
and used for Her-2/Neu expression in the breast cancer
patients and the prostate stem cell antigen expression in
the prostate cancer patients [31,32].
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